Published on Jun 2, 2015 - Last week, NIH’s National Institute of Allergy and Infectious Diseases (NIAID) released the exciting results of the Strategic Timing of Antiretroviral Treatment (START) study, a randomized, controlled clinical trial to more clearly define the optimal time and benefits for people with HIV to begin antiretroviral therapy (ART).
Given the implications of the study, AIDS.gov sat down with NIAID Director Anthony Fauci to ask him about the study and what it means for the global treatment of people living with HIV. We also asked him to share his thoughts on the state of HIV treatment today.
